It is noteworthy that a hormone-deprived environment is what is realized in breast cancer patients treated with Aromatase Inhibitors (AIs), the category of drugs that is becoming one of the most widely used for breast cancer patients with ERα+ tumors. Here, CYP19A1 is linked to breast carcinoma.